Figure 3.
![Figure 3. GRN163 induced progressive telomeric shortening in myeloma and lymphoma cells for 40 days of continuous treatment. Mean telomere lengths were evaluated in 3 cell lines (CAG [panel A], HT [panel B], and U266 [panel C]) with varying initial telomere lengths at intervals of 4 to 7 days during continuous PBS or GRN163 (10 μM) treatment. Results from all 3 cell lines demonstrated that GRN163 treatment (10 μM) consistently resulted in more rapid telomere shortening than PBS-treated controls in all cell lines. Representative TRF blots of CAG MM (initial TRF, 2.7 kb), HT NHL (initial TRF, 11 kb), and U266 MM cells (initial TRF, 9.0 kb) are shown.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/103/1/10.1182_blood-2003-02-0546/6/h80145467003.jpeg?Expires=1743567289&Signature=fbg7-4Xz-RcKXpYOn5eH8VS8QXTcrcFxa2WoiLvdDCniFf-THEKi9JjqYOh6bNuGnf58dYkVT9htwh9FiDjbim92bIk~7qV~wCpTENbWxD8J5Cei6OS8p2piNKlQ4Wp3XF6dh9XoIlind22-RrumN3ieFIo3yZzOtibVv2wvHNhxZm302dW1fCC5GQSRbjzZc42igaRISa69Ax37FisPstngJXoPQb3S5FBiy3VYgodciGbCczsyygc4QQHajzPSzGDTQZn5HYXS6s~2qou6lJ7sFEc1uUdKUSsHuOpbc2IFK1C28BclPB2xNmWL4iEy-NTlxR7H8JwK7GqpjSenvw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
GRN163 induced progressive telomeric shortening in myeloma and lymphoma cells for 40 days of continuous treatment. Mean telomere lengths were evaluated in 3 cell lines (CAG [panel A], HT [panel B], and U266 [panel C]) with varying initial telomere lengths at intervals of 4 to 7 days during continuous PBS or GRN163 (10 μM) treatment. Results from all 3 cell lines demonstrated that GRN163 treatment (10 μM) consistently resulted in more rapid telomere shortening than PBS-treated controls in all cell lines. Representative TRF blots of CAG MM (initial TRF, 2.7 kb), HT NHL (initial TRF, 11 kb), and U266 MM cells (initial TRF, 9.0 kb) are shown.
